汇宇制药股价跌5.03%，泓德基金旗下1只基金重仓，持有5万股浮亏损失5.6万元

Core Viewpoint - Huyou Pharmaceutical experienced a decline of 5.03% in stock price, currently trading at 21.16 CNY per share, with a total market capitalization of 8.963 billion CNY [1] Company Overview - Sichuan Huyou Pharmaceutical Co., Ltd. was established on October 12, 2010, and went public on October 26, 2021. The company specializes in the research, production, and sales of drugs in the oncology field and complex injectable drugs [1] - The main revenue composition of the company includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Fund Holdings - Huyou Pharmaceutical is a significant holding in the Hongde Medical Innovation Mixed Fund A (012481), which held 50,000 shares, accounting for 6.13% of the fund's net value, ranking as the ninth largest holding [2] - The fund has reported a year-to-date return of 48.5% and a one-year return of 44.18%, with a total fund size of 14.8031 million CNY [2] - The fund manager, Cao Zhaoxu, has a tenure of 4 years and 306 days, with the fund's best and worst returns during his management being -1.98% and -35.88%, respectively [2]